Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
For Male Hypogonadism Workup Treatment, frame the differential by acuity and pathophysiology, then align diagnostics to the leading hypotheses. Prioritize stabilization while obtaining high‑yield studies such as BMP (Electrolytes/anion gap), Ketones (if DKA) (Ketoacidosis), ABG/VBG (Acid–base status). Incorporate bedside imaging and targeted labs to define severity and identify complications; synthesize results with clinical trajectory to refine the working diagnosis and disposition needs.
Treatment Strategy & Disposition
Initiate disease‑directed therapy alongside supportive care, titrating to objective response. Pharmacologic options commonly include Insulin, Dextrose, Electrolytes (K+, Mg2+). Use validated frameworks (e.g., Monitoring on TRT) to guide escalation and site of care. Address precipitating factors, de‑escalate empiric therapies with data, and arrange follow‑up for monitoring and risk‑factor modification; admit patients with instability, high risk of deterioration, or needs for close monitoring.
Management Notes
Avoid TRT in men seeking fertility—consider clomiphene or hCG. Use shared decision-making for CV risk.
Epidemiology / Risk Factors
- Diabetes and endocrine disorders depending on topic
Investigations
Test | Role / Rationale | Typical Findings | Notes |
---|---|---|---|
BMP | Electrolytes/anion gap | Derangements | |
Ketones (if DKA) | Ketoacidosis | Positive | |
ABG/VBG | Acid–base status | Acidosis/alkalosis |
Monitoring on TRT
Parameter | When |
---|---|
Hematocrit | Baseline, 3–6 mo, then annually (hold if >54%) |
PSA/DRE (men >40–50) | Baseline and per screening guidance |
Testosterone level | 2–3 months after initiation/titration |
Lipids/A1c | As clinically indicated |
Sleep apnea/LUTS | Reassess symptoms |
Pharmacology
Medication | Mechanism | Onset | Role in Therapy | Limitations |
---|---|---|---|---|
Acetaminophen | Analgesic/antipyretic | Hours | Symptom control as appropriate | Hepatotoxicity (overdose) |
Ondansetron | 5-HT3 antagonism | Minutes | Antiemesis if needed | QT prolongation |
Prognosis / Complications
- Improves with derangement correction; recurrence if triggers persist
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
References
- Endocrine Society — Testosterone Therapy — Link